Propafenone-induced torsade de pointes: cross-reactivity with quinidine.
A 77-year-old female with new onset atrial fibrillation occurring in the absence of structural heart disease developed torsade de pointes during therapy with quinidine bisulfate 500 mg orally every 8 hours. Ten days after quinidine therapy had been discontinued she developed torsade de pointes while receiving propafenone 300 mg orally every 8 hours. This case demonstrates that propafenone may be associated with torsade de pointes and suggests a cross-reactivity between this effect and prior occurrence of torsade de pointes on Class IA antiarrhythmic drug therapy.
Hii
J T
JT
Department of Medicine, Foothills General Hospital, Calgary, Alberta, Canada.
Wyse
D G
DG
Gillis
A M
AM
Cohen
J M
JM
Mitchell
L B
LB
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D003429:Cross Reactions; D004562:Electrocardiography; D005260:Female; D006801:Humans; D011405:Propafenone / Q000009:adverse effects* / Q000627:therapeutic use; D011802:Quinidine / Q000009:adverse effects* / Q000627:therapeutic use; D016171:Torsades de Pointes / Q000139:chemically induced*
D000889:Anti-Arrhythmia Agents; D011405:Propafenone; C009764:quinidine bisulfate; D011802:Quinidine